Gw pharmaceuticals plc (GWPH)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17
Cash flows from operating activities
Net loss

-7,965

-24,946

-13,757

79,748

-50,064

-71,906

-79,879

-84,011

-69,461

-61,816

Adjustments to reconcile net loss to net cash used in operating activities:
Foreign exchange loss

-60

-3,127

1,300

-85

-797

-742

-1,167

-3,057

-873

180

Share-based compensation

11,361

12,397

12,303

12,188

11,142

9,683

9,609

9,567

6,859

5,592

Depreciation and amortization

2,656

2,144

2,288

2,391

2,417

2,534

2,407

2,413

2,307

2,163

Deferred income taxes

-

-

-

-

-

-1,265

-572

-721

2,128

-1,152

Other

-27

-

-

-

-

-

-

-

-

-8

Changes in operating assets and liabilities:
Accounts receivable, net

13,630

6,932

9,767

12,926

14,998

2,125

158

103

320

223

Inventory

8,928

13,564

10,491

12,775

14,295

14,460

16,525

-1,829

-672

-378

Prepaid expenses and other current assets

-5,377

-5,038

8,050

5,945

874

3,635

7,134

-22,631

492

516

Other assets

-885

-920

-1,426

-883

-659

47

149

246

3

166

Accounts payable

8,585

1,966

-4,649

1,490

1,998

-1,211

884

2,504

652

-1,802

Current tax liabilities

1,726

-362

-1,220

1,273

-654

878

-1,386

-774

-2,684

4,898

Accrued liabilities

-16,953

13,934

15,289

7,559

6,328

5,942

9,904

10,604

-7,005

3,004

Other liabilities

-1,799

29

249

-1,354

-838

410

-

-

-

-

Other current liabilities

-

-

-

-

-

-

-

-

1,103

-

Long-term liabilities

-

-

-

-

-

-

-

-

-30

-

Net cash used in operating activities

-18,598

-15,947

-17,661

-31,479

-58,382

-74,460

-81,999

-32,910

-65,401

-51,558

Cash flows from investing activities
Additions to property, plant and equipment

6,361

10,471

7,400

10,428

12,087

18,687

8,939

8,619

6,056

7,748

Additions to capitalized software

535

-

-

-

199

-

-

-

-

-

Additions to intangible assets

6,404

-

-

-

-

63

66

645

338

993

Net cash used in investing activities

-13,300

-11,390

-7,566

92,871

-12,286

-18,750

-8,488

-9,264

-6,394

-8,741

Cash flows from financing activities
Proceeds from issuance of ordinary shares, net of issuance costs

-

-

-

-

-

324,638

-

-

-

297,932

Proceeds from exercise of stock options

3

0

0

2,105

773

-

617

1

1

1

Payments on finance leases

73

72

67

71

179

40

68

71

72

-

Payments on landlord financing obligation

143

139

131

135

138

130

126

134

137

125

Net cash (used in) provided by financing activities

-213

-211

-198

1,899

456

324,468

423

-204

-208

297,743

Effect of exchange rate changes on cash

-3,887

9,799

-3,576

-1,277

384

5,326

5,037

-4,917

11

-371

Net decrease in cash and cash equivalents

-35,998

-17,749

-29,001

62,014

-69,828

236,584

-85,027

-47,295

-71,992

237,073

Supplemental disclosure of cash flow information:
Income taxes paid

10

3,410

3,145

3,819

88

-

1,101

1,568

1,672

-

Interest paid

285

282

272

268

265

198

297

313

325

-

Supplemental disclosure of noncash information:
Property and equipment purchases in accounts payable and accrued liabilities

1,661

-611

678

142

714

1,899

141

-1,642

1,823

-

Right-of-use asset obtained in exchange for operating liabilities

275

-

-

-

-

-

-

-

-

-